MDSpire - Takeaway
Commentary & Perspectives

Could Mass Spec Overcome the CAR T Solid Tumor Barrier?

Joey Sheff explains how proteomics is revealing targets, guiding CAR design, and predicting function in solid tumors.

  • April 1, 2026

  • 8 min

Share

  • 1

    CAR T therapy shows promise for blood cancers, limited in solid tumors due to target challenges.

  • 2

    Analytical science is key for understanding CAR T functions.

  • 3

    Mass spectrometry plays a critical role in identifying targets.

  • 4

    Development of CAR therapies for solid tumors is underway with significant potential.

  • 5

    Research at NRC focuses on data-driven CAR T therapy advancements.

  • 6

    Novel analytics may guide improved therapy design and outcomes.

  • 7

    Future CAR T products could be universal and off-the-shelf.

Original Source(s)

Could Mass Spec Overcome the CAR T Solid Tumor Barrier?

  • April 1, 2026

Related Content

Early Results From a Trial of Active Surveillance for Low-Risk DCIS are ‘Reassuring,’ Say Researchers

“For women with low-risk DCIS, these interim results are reassuring. There is currently no indication that active surveillance leads to worse early outcomes compared with immediate surgery. It’s impor...

From One Stem Cell to Millions of Cancer Killers

A three-step engineering strategy generates vast numbers of potent NK immune cells – potentially slashing the cost and scaling of cancer immunotherapy

  • April 1, 2026

  • 1 min
AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC

An artificial intelligence (AI) multiagent system demonstrated correct and complete reasoning in determining the use of immunotherapy for patients with non–small cell lung cancer (NSCLC) in the first-...